GT200800265A - Pirido (3,2-e)piracinas, su uso como inhibidores de fosfadiesterasa 10, y procesos para prepararlas. - Google Patents
Pirido (3,2-e)piracinas, su uso como inhibidores de fosfadiesterasa 10, y procesos para prepararlas.Info
- Publication number
- GT200800265A GT200800265A GT200800265A GT200800265A GT200800265A GT 200800265 A GT200800265 A GT 200800265A GT 200800265 A GT200800265 A GT 200800265A GT 200800265 A GT200800265 A GT 200800265A GT 200800265 A GT200800265 A GT 200800265A
- Authority
- GT
- Guatemala
- Prior art keywords
- piracinas
- pirido
- inhibitors
- prepare
- processes
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Virology (AREA)
- Psychology (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Vascular Medicine (AREA)
- Communicable Diseases (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
LA INENCIÓN SE RELACIONA CON PIRIDO[3,2-E]PIRACINAS, CON PROCESOS PARA PREPARARLAS, CON PREPARACIONES FARMACÉUTICAS LA CUALES COMPRENDEN ESOS COMPUESTOS Y CON EL USO FARMACÉUTICO DE ESOS COMPUESTOS, LOS CUALES SON INHIBIDORES DE FOSFODIESTERASA 10, COMO COMPUESTOS ACTIVOS PARA TRATAR ENFERMEDADES DE MAMÍFEROS INCLUYENDO HUMANOS LOS CUALES PUEDEN SER DIFERENCIADOS POR EL USO DE COMPUESTOS DE ACUERDO A LA INVENCIÓN PARA INHIBIR LA ACTIVIDAD DE LA FOSFODIESTERASA 10 EN EL SISTEMA NERVIOSO CENTRAL. DE MANERA MÁS PARTICULAR, LA INVENCIÓN SE RELACIONA CON EL TRATAMIENTO DE TRASTORNOS NEUROLÓGICOS Y PSIQUIÁTRICOS, POR EJEMPLO PSICOSIS Y TRASTORNOS QUE COMPRENDEN DÉFICITS CONGNOSCITIVOS COMO SÍNTOMAS. T2008
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US80924206P | 2006-05-30 | 2006-05-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
GT200800265A true GT200800265A (es) | 2010-07-22 |
Family
ID=38441604
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GT200800265A GT200800265A (es) | 2006-05-30 | 2008-11-27 | Pirido (3,2-e)piracinas, su uso como inhibidores de fosfadiesterasa 10, y procesos para prepararlas. |
Country Status (21)
Country | Link |
---|---|
US (2) | US7550465B2 (es) |
EP (1) | EP2021342A1 (es) |
JP (1) | JP2009538853A (es) |
KR (1) | KR20090013834A (es) |
CN (1) | CN101454324A (es) |
AR (1) | AR061206A1 (es) |
AU (1) | AU2007267392A1 (es) |
BR (1) | BRPI0712132A2 (es) |
CA (1) | CA2651849A1 (es) |
CL (1) | CL2007001554A1 (es) |
CR (1) | CR10358A (es) |
GT (1) | GT200800265A (es) |
IL (1) | IL193740A0 (es) |
MX (1) | MX2008014569A (es) |
NO (1) | NO20085326L (es) |
PE (1) | PE20080711A1 (es) |
RU (1) | RU2008152440A (es) |
SV (1) | SV2009003048A (es) |
TW (1) | TW200817400A (es) |
WO (1) | WO2007137820A1 (es) |
ZA (1) | ZA200807517B (es) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW200815436A (en) * | 2006-05-30 | 2008-04-01 | Elbion Ag | 4-amino-pyrido[3,2-e]pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them |
ES2536906T3 (es) | 2006-12-13 | 2015-05-29 | Aska Pharmaceutical Co., Ltd. | Derivado de quinoxalina |
US20090143392A1 (en) * | 2007-11-30 | 2009-06-04 | Elbion Gmbh | Methods of Treating Obesity and Metabolic Disorders |
WO2009070584A1 (en) * | 2007-11-30 | 2009-06-04 | Wyeth | Aryl and heteroaryl fused imidazo[1,5-a]pyrazines as inhibitors of phosphodiesterase 10 |
US20090143361A1 (en) * | 2007-11-30 | 2009-06-04 | Elbion Gmbh | Pyrido[3,2-E]Pyrazines, Process For Preparing The Same, And Their Use As Inhibitors Of Phosphodiesterase 10 |
CN102065861B (zh) * | 2008-05-07 | 2013-10-16 | H.隆德贝克有限公司 | 反式-4-((1r,3s)-6-氯-3-苯基茚满-1-基)-1,2,2-三甲基哌嗪用于改善认知的用途 |
WO2010054253A1 (en) * | 2008-11-07 | 2010-05-14 | Biotie Therapies Gmbh | Triazine derivatives as inhibitors of phosphodiesterases |
BR112013001303A2 (pt) * | 2010-07-20 | 2016-05-17 | Cyrenaic Pharmaceuticals Inc | métodos de uso de derivados de amida cíclica para tratar esquizofrenia |
ES2914120T3 (es) * | 2010-07-20 | 2022-06-07 | Minerva Neurosciences Inc | Procedimientos de uso de derivados de amida cíclicos para tratar trastornos mediados por el receptor sigma |
US9540379B2 (en) | 2011-01-31 | 2017-01-10 | Boehringer Ingelheim International Gmbh | (1,2,4)triazolo[4,3-A]quinoxaline derivatives as inhibitors of phosphodiesterases |
JP2014510055A (ja) | 2011-02-18 | 2014-04-24 | アラーガン インコーポレイテッド | ホスホジエステラーゼ10(pde10a)阻害剤としての置換6,7−ジアルコキシ−3−イソキノリノール誘導体 |
US9938269B2 (en) | 2011-06-30 | 2018-04-10 | Abbvie Inc. | Inhibitor compounds of phosphodiesterase type 10A |
US9056863B2 (en) * | 2011-09-09 | 2015-06-16 | H. Lundbeck A/S | Substituted 2,3,5,9,9B-pentaazacyclopenta[a]naphthalenes and uses thereof |
EP2780324B1 (en) | 2011-11-09 | 2017-05-17 | Abbvie Deutschland GmbH & Co. KG | Heterocyclic carboxamides useful as inhibitors of phosphodiesterase type 10a |
US20130116241A1 (en) | 2011-11-09 | 2013-05-09 | Abbvie Inc. | Novel inhibitor compounds of phosphodiesterase type 10a |
NZ631258A (en) | 2012-04-25 | 2016-11-25 | Takeda Pharmaceuticals Co | Nitrogenated heterocyclic compound |
US9527841B2 (en) | 2012-07-13 | 2016-12-27 | Takeda Pharmaceutical Company Limited | Substituted pyrido[2,3-b]pyrazines as phosphodiesterase 2A inhibitors |
US20140045856A1 (en) * | 2012-07-31 | 2014-02-13 | Boehringer Ingelheim International Gmbh | 4-Methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalenes |
US9464085B2 (en) | 2012-08-17 | 2016-10-11 | AbbVie Deutschland GmbH & Co. KG | Inhibitor compounds of phosphodiesterase type 10A |
KR20150056844A (ko) | 2012-09-17 | 2015-05-27 | 아비에 도이치란트 게엠베하 운트 콤파니 카게 | 포스포디에스테라제 타입 10a의 신규 억제제 화합물 |
WO2014071044A1 (en) | 2012-11-01 | 2014-05-08 | Allergan, Inc. | Substituted 6,7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (pde10a) |
US9790203B2 (en) | 2012-11-26 | 2017-10-17 | Abbvie Inc. | Inhibitor compounds of phosphodiesterase type 10A |
US9200005B2 (en) | 2013-03-13 | 2015-12-01 | AbbVie Deutschland GmbH & Co. KG | Inhibitor compounds of phosphodiesterase type 10A |
AU2014230745A1 (en) | 2013-03-14 | 2015-09-03 | AbbVie Deutschland GmbH & Co. KG | Novel inhibitor compounds of phosphodiesterase type 10A |
EP2975031A4 (en) | 2013-03-14 | 2017-04-19 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
JP6411342B2 (ja) | 2013-07-03 | 2018-10-24 | 武田薬品工業株式会社 | アミド化合物 |
JP6427491B2 (ja) | 2013-07-03 | 2018-11-21 | 武田薬品工業株式会社 | 複素環化合物 |
WO2015006689A1 (en) | 2013-07-12 | 2015-01-15 | University Of South Alabama | Treatment and diagnosis of cancer and precancerous conditions using pde10a inhibitors and methods to measure pde10a expression |
US9200016B2 (en) | 2013-12-05 | 2015-12-01 | Allergan, Inc. | Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A) |
JP2022501335A (ja) | 2018-09-28 | 2022-01-06 | 武田薬品工業株式会社 | 自閉症スペクトラム障害を治療または予防するためのバリポデクト(Balipodect) |
CN114524808B (zh) * | 2022-02-21 | 2023-10-24 | 深圳市儿童医院 | 一种吡唑衍生物及其作为pde10抑制剂的用途 |
CN114524806A (zh) * | 2022-02-22 | 2022-05-24 | 深圳市儿童医院 | 一种三氮唑衍生物及其作为pde10抑制剂的用途 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5055465A (en) * | 1989-05-31 | 1991-10-08 | Berlex Laboratories, Inc. | Imidazoquinoxalinones, their aza analogs and process for their preparation |
JP3147902B2 (ja) * | 1991-06-14 | 2001-03-19 | ファルマシア・アンド・アップジョン・カンパニー | イミダゾ〔1,5−a〕キノキサリン |
DE19510965A1 (de) * | 1995-03-24 | 1996-09-26 | Asta Medica Ag | Neue Pyrido/3,2-e/pyrazinone mit antiasthmatischer Wirksamkeit und Verfahren zu deren Herstellung |
US20030032579A1 (en) * | 2001-04-20 | 2003-02-13 | Pfizer Inc. | Therapeutic use of selective PDE10 inhibitors |
IL149106A0 (en) | 2001-04-20 | 2002-11-10 | Pfizer Prod Inc | Therapeutic use of selective pde10 inhibitors |
-
2007
- 2007-05-18 TW TW096117906A patent/TW200817400A/zh unknown
- 2007-05-24 US US11/753,207 patent/US7550465B2/en not_active Expired - Fee Related
- 2007-05-29 MX MX2008014569A patent/MX2008014569A/es active IP Right Grant
- 2007-05-29 AU AU2007267392A patent/AU2007267392A1/en not_active Abandoned
- 2007-05-29 EP EP07725639A patent/EP2021342A1/en not_active Withdrawn
- 2007-05-29 AR ARP070102310A patent/AR061206A1/es unknown
- 2007-05-29 CA CA002651849A patent/CA2651849A1/en not_active Abandoned
- 2007-05-29 WO PCT/EP2007/004748 patent/WO2007137820A1/en active Application Filing
- 2007-05-29 JP JP2009512482A patent/JP2009538853A/ja active Pending
- 2007-05-29 CN CNA2007800193040A patent/CN101454324A/zh active Pending
- 2007-05-29 RU RU2008152440/04A patent/RU2008152440A/ru not_active Application Discontinuation
- 2007-05-29 KR KR1020087031860A patent/KR20090013834A/ko not_active Application Discontinuation
- 2007-05-29 BR BRPI0712132-6A patent/BRPI0712132A2/pt not_active IP Right Cessation
- 2007-05-30 CL CL2007001554A patent/CL2007001554A1/es unknown
- 2007-05-30 PE PE2007000674A patent/PE20080711A1/es not_active Application Discontinuation
-
2008
- 2008-08-28 IL IL193740A patent/IL193740A0/en unknown
- 2008-08-29 ZA ZA200807517A patent/ZA200807517B/xx unknown
- 2008-10-02 SV SV2008003048A patent/SV2009003048A/es active IP Right Grant
- 2008-10-10 CR CR10358A patent/CR10358A/es not_active Application Discontinuation
- 2008-11-27 GT GT200800265A patent/GT200800265A/es unknown
- 2008-12-19 NO NO20085326A patent/NO20085326L/no not_active Application Discontinuation
-
2009
- 2009-05-19 US US12/454,537 patent/US20090239874A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AR061206A1 (es) | 2008-08-13 |
BRPI0712132A2 (pt) | 2012-01-17 |
SV2009003048A (es) | 2009-02-11 |
CA2651849A1 (en) | 2007-12-06 |
CL2007001554A1 (es) | 2008-01-18 |
ZA200807517B (en) | 2009-06-24 |
RU2008152440A (ru) | 2010-07-10 |
KR20090013834A (ko) | 2009-02-05 |
JP2009538853A (ja) | 2009-11-12 |
AU2007267392A1 (en) | 2007-12-06 |
EP2021342A1 (en) | 2009-02-11 |
MX2008014569A (es) | 2008-12-03 |
NO20085326L (no) | 2008-12-19 |
CN101454324A (zh) | 2009-06-10 |
PE20080711A1 (es) | 2008-06-14 |
IL193740A0 (en) | 2009-05-04 |
CR10358A (es) | 2009-01-07 |
TW200817400A (en) | 2008-04-16 |
WO2007137820A1 (en) | 2007-12-06 |
US20090239874A1 (en) | 2009-09-24 |
US7550465B2 (en) | 2009-06-23 |
US20080027064A1 (en) | 2008-01-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GT200800265A (es) | Pirido (3,2-e)piracinas, su uso como inhibidores de fosfadiesterasa 10, y procesos para prepararlas. | |
CL2011002837A1 (es) | Compuestos derivados de 1,2,4-triazolo[4,3-a]piridina, moduladores alostericos positivos de receptores mglur2; composicion farmaceutica; proceso para prepararla; y su uso en el tratamiento o la prevencion de un trastorno del sistema nervioso central tal como la ansiedad, esquizofrenia y migraña, entre otros. | |
CL2009000699A1 (es) | Compuestos derivados de 6-heteroaril-imidazo[1,2-a]piridinas polisustituidas; composicion farmaceutica; procedimiento de sintesis; compuestos intermediarios; y su uso para tratar o prevenir enfermedades neurodegenerativas, psiquiatricas, inflamatorias, traumatismos cerebrales y de la epilepsia, osteoporosis, cancer, parkinson, entre otras. | |
CO6602133A2 (es) | Derivados de i,idazo(1,2-a)pirazina y su uso para la prevencion o tratamiento de trastornos y enfermedades neurologicas, siquiatricas y metabolicas | |
CO6870032A2 (es) | Nuevos compuestos inhibidores de la fosfodiesterasa tipo 10a | |
CL2008002744A1 (es) | Compuestos derivados de 1,3-disustituidos-4-fenil-1h-piridin-2-ona, moduladores alostericos del receptor glutamatérgico mglur2; composición farmacéutica y uso de los compuestos en el tratamiento de afecciones neurológicas y siquiatricas mediadas por mglur2. | |
CL2011002838A1 (es) | Compuestos derivados de 1,2,4-triazolo[4,3-a]piridina, moduladores alostéricos de receptores mglur2; composición farmacéutica; proceso para prepararla; y su uso en el tratamiento o la prevención de un trastorno del sistema nervioso central seleccionado de ansiedad y esquizofrenia, entre otros. | |
CO6321241A2 (es) | Derivados de 1,3,4- tiadiazol espiro condensados para la inhibicion de la actividad de quinesina (ksp) | |
CO6531468A2 (es) | Derivados de imidazo[1,2-b] piridazina y su uso como inhibidores de pde 10 | |
CL2009000696A1 (es) | Compuestos polisustituidos derivados de 2-aril-6-fenil-imidazo[1,2-a]piridinas; procedimiento de preparacion; compuestos intermediarios; composicion farmaceutica; y su uso para el tratamiento y la prevencion de enfermedades neurodegenerativas, de traumatismos cerebrales y epilepsia, enfermedades psiquiatricas, enfermedades inflamatorias, entre otras. | |
CL2015002529A1 (es) | Compuestos de tetrahidropirrolotiazina | |
ECSP077421A (es) | Compuestos y composiciones como inhibidores de la actividad del receptor canabinoide 1 | |
WO2010006130A3 (en) | Pde-10 inhibitors | |
GT200600193A (es) | Imidazoquinolines como inhibidores de lipidos kinase | |
GT200500367A (es) | Derivados novedosos pirrolidilo de compuestos heteroaromaticos | |
UY33616A (es) | Compuestos con estructura de imidazotriazinona | |
PA8806201A1 (es) | Imidazo pirazinas fusionadas | |
CL2008003577A1 (es) | Compuestos derivados de imidazo[1,5-a] pirido[3,2-e]pirazina, 2, 6, 7, 9 tetrasustituidos; inhibidores de fosfodiesterasa 10; procedimiento de preparación; composición farmacéutica que comprende a dichos compuestos; y su uso para tratar enfermedades relacionadas con el sistema nervioso central, obesidad y trastornos del metabolismo. | |
GT200800184A (es) | Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa-iv para el tratamiento o prevencion de diabetes. | |
CL2012001073A1 (es) | Compuestos derivados de pirido[4,3-d]pirimidin-5-ona, sus composiciones farmaceuticas y su uso como inhibidores de quinasa para tratar asma, epoc, colitis ulcerante, bronquitis, lupus, cancer de mamas, enfermedad de alzheimer, enfermedad de parkinson, osteoporosis, esclerosis multiple, diabetes, trastornos oculares, restenosis, enfermedades inflamatorias. | |
CR20140085A (es) | Inhibidores de pde10 de pirimidina | |
ECSP088366A (es) | 1,2-diarilimidazoles para uso como moduladores de cb1 | |
CL2011002206A1 (es) | Compuestos derivados de benzofurano sustituidos, moduladores del señalador igf1 o activador de la proteina quinasa b; composicion farmaceutica que los comprende; utiles en el tratamiento de enfermedades del snc, tales como alzheimer, entre otras. | |
UY28839A1 (es) | Agentes terapeuticos | |
WO2012044562A3 (en) | Pyrazolopyrimidine pde10 inhibitors |